Shanghai Kehua Bio-Engineering Co Ltd

SHE:002022 China Medical Devices
Market Cap
$427.62 Million
CN¥3.14 Billion CNY
Market Cap Rank
#12440 Global
#3088 in China
Share Price
CN¥6.10
Change (1 day)
+2.01%
52-Week Range
CN¥5.24 - CN¥8.06
All Time High
CN¥29.42
Categories
Companies in China Medical Devices
About

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated co… Read more

Shanghai Kehua Bio-Engineering Co Ltd (002022) - Net Assets

Latest net assets as of September 2025: CN¥3.70 Billion CNY

Based on the latest financial reports, Shanghai Kehua Bio-Engineering Co Ltd (002022) has net assets worth CN¥3.70 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.17 Billion) and total liabilities (CN¥1.47 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥3.70 Billion
% of Total Assets 71.63%
Annual Growth Rate 16.04%
5-Year Change 2.14%
10-Year Change 130.78%
Growth Volatility 29.64

Shanghai Kehua Bio-Engineering Co Ltd - Net Assets Trend (2001–2024)

This chart illustrates how Shanghai Kehua Bio-Engineering Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Shanghai Kehua Bio-Engineering Co Ltd (2001–2024)

The table below shows the annual net assets of Shanghai Kehua Bio-Engineering Co Ltd from 2001 to 2024.

Year Net Assets Change
2024-12-31 CN¥3.98 Billion -20.10%
2023-12-31 CN¥4.98 Billion -14.83%
2022-12-31 CN¥5.85 Billion +14.05%
2021-12-31 CN¥5.13 Billion +31.60%
2020-12-31 CN¥3.90 Billion +44.92%
2019-12-31 CN¥2.69 Billion +10.72%
2018-12-31 CN¥2.43 Billion +16.88%
2017-12-31 CN¥2.08 Billion +9.39%
2016-12-31 CN¥1.90 Billion +10.15%
2015-12-31 CN¥1.73 Billion +36.13%
2014-12-31 CN¥1.27 Billion +4.93%
2013-12-31 CN¥1.21 Billion +11.20%
2012-12-31 CN¥1.09 Billion +5.90%
2011-12-31 CN¥1.03 Billion +10.15%
2010-12-31 CN¥931.34 Million +17.47%
2009-12-31 CN¥792.82 Million +23.16%
2008-12-31 CN¥643.75 Million +32.33%
2007-12-31 CN¥486.48 Million +22.23%
2006-12-31 CN¥398.02 Million +4.55%
2005-12-31 CN¥380.71 Million -0.29%
2004-12-31 CN¥381.82 Million +140.25%
2003-12-31 CN¥158.92 Million +8.70%
2002-12-31 CN¥146.21 Million +12.50%
2001-12-31 CN¥129.97 Million --

Equity Component Analysis

This analysis shows how different components contribute to Shanghai Kehua Bio-Engineering Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 17991.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥2.44 Billion 72.91%
Common Stock CN¥514.32 Million 15.35%
Other Components CN¥393.02 Million 11.73%
Total Equity CN¥3.35 Billion 100.00%

Shanghai Kehua Bio-Engineering Co Ltd Competitors by Market Cap

The table below lists competitors of Shanghai Kehua Bio-Engineering Co Ltd ranked by their market capitalization.

Company Market Cap
Beijing SPC Environment Protection Tech Co Ltd
SHE:002573
 		$325.38 Million
Braskem S.A.
SA:BRKM3
 		$325.42 Million
TCI Co Ltd
TWO:8436
 		$325.58 Million
Hudson Pacific Properties Inc
NYSE:HPP
 		$325.60 Million
NOTE AB SK-50
F:NQA
 		$325.23 Million
Chief Telecom Inc
TWO:6561
 		$325.14 Million
Momentum Group AB Series B
LSE:0RTK
 		$325.03 Million
China Western Power Industrial Co Ltd
SHE:002630
 		$325.01 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shanghai Kehua Bio-Engineering Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 4,029,629,261 to 3,349,826,403, a change of -679,802,858 (-16.9%).
  • Net loss of 640,601,876 reduced equity.
  • Dividend payments of 24,442,043 reduced retained earnings.
  • Share repurchases of 101,017,583 reduced equity.
  • Other factors increased equity by 86,258,644.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥-640.60 Million -19.12%
Dividends Paid CN¥24.44 Million -0.73%
Share Repurchases CN¥101.02 Million -3.02%
Other Changes CN¥86.26 Million +2.58%
Total Change CN¥- -16.87%

Book Value vs Market Value Analysis

This analysis compares Shanghai Kehua Bio-Engineering Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.92x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 38.29x to 0.92x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-12-31 CN¥0.16 CN¥6.10 x
2002-12-31 CN¥0.18 CN¥6.10 x
2003-12-31 CN¥0.31 CN¥6.10 x
2004-12-31 CN¥1.04 CN¥6.10 x
2005-12-31 CN¥1.13 CN¥6.10 x
2006-12-31 CN¥1.14 CN¥6.10 x
2007-12-31 CN¥0.92 CN¥6.10 x
2008-12-31 CN¥1.23 CN¥6.10 x
2009-12-31 CN¥1.53 CN¥6.10 x
2010-12-31 CN¥1.84 CN¥6.10 x
2011-12-31 CN¥1.99 CN¥6.10 x
2012-12-31 CN¥2.07 CN¥6.10 x
2013-12-31 CN¥2.30 CN¥6.10 x
2014-12-31 CN¥2.55 CN¥6.10 x
2015-12-31 CN¥3.31 CN¥6.10 x
2016-12-31 CN¥3.60 CN¥6.10 x
2017-12-31 CN¥3.89 CN¥6.10 x
2018-12-31 CN¥4.24 CN¥6.10 x
2019-12-31 CN¥4.59 CN¥6.10 x
2020-12-31 CN¥6.12 CN¥6.10 x
2021-12-31 CN¥7.28 CN¥6.10 x
2022-12-31 CN¥9.03 CN¥6.10 x
2023-12-31 CN¥7.83 CN¥6.10 x
2024-12-31 CN¥6.63 CN¥6.10 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shanghai Kehua Bio-Engineering Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -19.12%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -36.41%
  • • Asset Turnover: 0.34x
  • • Equity Multiplier: 1.56x
  • Recent ROE (-19.12%) is below the historical average (20.50%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 31.96% 19.86% 0.79x 2.04x CN¥17.99 Million
2002 35.32% 18.44% 0.77x 2.50x CN¥22.86 Million
2003 35.67% 16.46% 0.90x 2.41x CN¥25.70 Million
2004 12.84% 17.92% 0.54x 1.33x CN¥9.48 Million
2005 16.56% 18.77% 0.66x 1.34x CN¥22.35 Million
2006 19.85% 21.99% 0.70x 1.29x CN¥37.01 Million
2007 25.70% 29.57% 0.65x 1.33x CN¥72.08 Million
2008 27.02% 34.09% 0.66x 1.20x CN¥104.61 Million
2009 27.04% 32.90% 0.67x 1.23x CN¥128.78 Million
2010 25.04% 28.83% 0.72x 1.21x CN¥135.30 Million
2011 23.17% 25.95% 0.73x 1.23x CN¥128.88 Million
2012 23.49% 23.66% 0.79x 1.26x CN¥137.72 Million
2013 25.47% 25.87% 0.81x 1.21x CN¥175.11 Million
2014 23.23% 23.97% 0.85x 1.14x CN¥166.30 Million
2015 12.58% 18.22% 0.56x 1.24x CN¥43.22 Million
2016 12.60% 16.64% 0.60x 1.26x CN¥47.92 Million
2017 10.90% 13.66% 0.59x 1.36x CN¥18.01 Million
2018 9.54% 10.44% 0.57x 1.61x CN¥-9.94 Million
2019 11.60% 11.32% 0.65x 1.57x CN¥37.68 Million
2020 36.36% 27.49% 0.70x 1.90x CN¥828.11 Million
2021 34.96% 27.89% 0.70x 1.80x CN¥966.58 Million
2022 35.96% 24.84% 0.79x 1.83x CN¥1.25 Billion
2023 -5.81% -9.70% 0.35x 1.69x CN¥-636.98 Million
2024 -19.12% -36.41% 0.34x 1.56x CN¥-975.58 Million

Industry Comparison

This section compares Shanghai Kehua Bio-Engineering Co Ltd's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $3,616,655,219
  • Average return on equity (ROE) among peers: 19.25%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Shanghai Kehua Bio-Engineering Co Ltd (002022) CN¥3.70 Billion 31.96% 0.40x $325.38 Million
Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) $7.49 Billion 23.47% 0.34x $2.80 Billion
Double Medical Technology Inc (002901) $1.75 Billion 26.55% 0.28x $399.08 Million
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) $2.85 Billion 49.59% 0.20x $288.07 Million
Lepu Medical Tech Beijing (300003) $16.74 Billion 1.48% 0.47x $2.77 Billion
INKON Life Technology Co Ltd (300143) $116.90 Million 17.41% 0.92x $621.57 Million
Edan Instruments Inc (300206) $1.25 Billion 3.50% 0.14x $527.51 Million
Guangdong Biolight Meditech Co Ltd (300246) $1.29 Billion -5.53% 0.94x $377.92 Million
Beijing Leadman Biochemistry Co Ltd (300289) $105.32 Million 39.32% 0.45x $271.42 Million
Sinocare Inc (300298) $946.01 Million 17.47% 0.11x $954.87 Million